Relypsa Inc. (NASDAQ:RLYP) has earned a consensus recommendation of “Hold” from the seventeen ratings firms that are presently covering the stock. Twelve research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $36.76.

A number of equities analysts have recently commented on RLYP shares. Vetr lowered shares of Relypsa from a “strong-buy” rating to a “strong sell” rating and set a $14.50 price target on the stock. in a research report on Tuesday, June 21st. BTIG Research reaffirmed a “buy” rating and set a $35.00 target price on shares of Relypsa in a research report on Wednesday, June 29th. Morgan Stanley reaffirmed an “underweight” rating and set a $9.00 target price on shares of Relypsa in a research report on Tuesday, July 12th. Cantor Fitzgerald set a $41.00 target price on shares of Relypsa and gave the stock a “buy” rating in a research report on Thursday, July 21st. Finally, Stifel Nicolaus reaffirmed a “buy” rating on shares of Relypsa in a research report on Tuesday, June 28th.

Shares of Relypsa (NASDAQ:RLYP) opened at 31.99 on Tuesday. Relypsa has a 12-month low of $10.26 and a 12-month high of $32.12. The company has a 50 day moving average of $30.31 and a 200-day moving average of $20.28.

Relypsa (NASDAQ:RLYP) last released its quarterly earnings results on Thursday, August 4th. The company reported ($1.87) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.56) by $0.31. The firm had revenue of $5.22 million for the quarter, compared to the consensus estimate of $5.45 million. Equities research analysts predict that Relypsa will post ($6.33) earnings per share for the current year.

In related news, major shareholder Orbimed Advisors Llc sold 4,043,600 shares of Relypsa stock in a transaction that occurred on Monday, July 25th. The stock was sold at an average price of $32.00, for a total value of $129,395,200.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder James D. Dondero sold 37,000 shares of Relypsa stock in a transaction that occurred on Thursday, August 11th. The stock was sold at an average price of $31.96, for a total value of $1,182,520.00. The disclosure for this sale can be found here.

Several institutional investors have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. raised its position in Relypsa by 8.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 117,888 shares of the company’s stock worth $2,181,000 after buying an additional 9,220 shares in the last quarter. Stifel Financial Corp bought a new position in Relypsa during the second quarter worth approximately $190,000. Family Management Corp raised its position in Relypsa by 84.7% in the second quarter. Family Management Corp now owns 34,450 shares of the company’s stock worth $637,000 after buying an additional 15,800 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its position in Relypsa by 16.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 26,794 shares of the company’s stock worth $496,000 after buying an additional 3,806 shares in the last quarter. Finally, Marshall Wace LLP raised its position in Relypsa by 3.1% in the second quarter. Marshall Wace LLP now owns 462,649 shares of the company’s stock worth $8,559,000 after buying an additional 13,876 shares in the last quarter.

Relypsa Company Profile

Relypsa, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients’ lives and even be life-threatening. The Company’s first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia.

5 Day Chart for NASDAQ:RLYP

Receive News & Stock Ratings for Relypsa Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc. and related stocks with our FREE daily email newsletter.